Updated with stock informationHuman Genome Sciences ( HGSI) has beaten lupus. The Rockville, Md.-based drugmaker announced Monday that its experimental drug Benlysta achieved a clinically and statistically significant improvement in disease response compared with placebo, according to results from a pivotal phase III study of lupus patients. If confirmed in a second phase III study due later this year, Benlysta likely will become the first new drug approved to treat lupus specifically in 50 years. Human Genome is partnered with GlaxoSmithKline ( GSK) for Benlysta's development and marketing. The success of the Benlysta study is a signal achievement for Human Genome Sciences, placing the company on the path toward its first blockbuster product. Human Genome shares were up 218.4% to $10.57 in Monday morning trading.